News & Analysis as of

Marijuana › NIDA

McCarter & English, LLP

DEA’s Plan to Reschedule Cannabis: Implications and Insights

McCarter & English, LLP on

Earlier this week, the Department of Justice proposed reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act. The move follows an August 2023 recommendation from the Department of Health...more

McGlinchey Stafford

Is THCA Legal? The State Line is the Bottom Line

McGlinchey Stafford on

Tetrahydrocannabinolic acid (THCA) is one of the most misunderstood and controversial cannabinoids in the Cannabis sativa (cannabis) plant. While booming in popularity, THCA is also a high-risk cannabinoid from a legal...more

Amundsen Davis LLC

Historic Cannabis Rescheduling on the Horizon? It's Up to the DEA Now

Amundsen Davis LLC on

In October of 2022, the Biden Administration started an official cannabis policy review process, which began with granting pardons to all people convicted of simple cannabis possession under federal law. At the time, this was...more

Perkins Coie

FDA Releases Guidance on Clinical Research into Cannabis-Derived Drugs

Perkins Coie on

The U.S. Food and Drug Administration (FDA) recently released new guidance on sourcing and product quality to companies conducting clinical research related to the development of human drugs involving cannabis or...more

Dunlap Bennett & Ludwig PLLC

Researching Potential Medical Benefits of Cannabis Moves a Step Closer – sort of.

Dunlap Bennett & Ludwig PLLC on

Cannabis legalization advocates are quick to point out a Catch-22 in current legalization debates. On one hand, Cannabis is a Schedule 1 drug under the Controlled Substances Act....more

Vicente LLP

NIDA Monopoly is Over: New DEA-Registered Cannabis Growers Can Supply Researchers with Product

Vicente LLP on

It seems like every day I read a new story about legislators, high-ranking federal officials, and frustrated advocates of marijuana research complaining that researchers still can't study the actual marijuana that people are...more

Womble Bond Dickinson

DEA Set to Allow More Facilities to Produce Marijuana for Research: A Victory for Cannabis Growers, Researchers and the DEA?

Womble Bond Dickinson on

Although many states have legalized marijuana for medicinal and/or recreational use, when it comes to using marijuana in a research setting, sources have been very limited.  The US Drug Enforcement Administration (DEA) has...more

Saul Ewing LLP

On Heels of Senate’s Adoption of Cannabis Research Bill, DEA Issues Rule to License More Research Cannabis Growers

Saul Ewing LLP on

On December 18, 2020, just three days after the U.S. Senate adopted the Cannabidiol and Marihuana Research Expansion Act (CMREA or the Act) (more on this below), the U.S. Drug Enforcement Administration (DEA or the...more

Womble Bond Dickinson

FDA Issues Guidance on Clinical Research for Cannabis Drugs

Womble Bond Dickinson on

On Tuesday, July 21, 2020, the U.S. Food and Drug Administration (FDA) released a new draft guidance, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research. The draft guidance is intended to...more

Kelley Drye & Warren LLP

House Subcommittee Holds Hearing on Current Cannabis Policies

Kelley Drye & Warren LLP on

On January 15, the Subcommittee on Health of the Committee on Energy and Commerce held its first ever legislative hearing to address federal cannabis policies. The subcommittee invited witness from three different agencies...more

10 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide